Skip to Main Content

Advertisement

Skip Nav Destination

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

Blood Adv (2022) 6 (11): 3201–3206.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement